Research programme: small molecule cardiovascular therapeutics - Gilead Sciences
Latest Information Update: 14 Jul 2010
At a glance
- Originator Gilead Sciences; University of Texas Southwestern Medical Center
- Developer Gilead Sciences; Novartis; University of Texas Southwestern Medical Center
- Class Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 14 Jul 2010 Discontinued - Preclinical for Heart failure in USA (unspecified route)
- 18 Nov 2006 Myogen has been acquired by Gilead Sciences
- 13 Jul 2006 Myogen and Novartis have extended their licensing agreement through October 2008